Pfizer (PFE) 1Q Earnings and Revenue Beat on Cancer Drug, Vaccine Sales

Shares of Pfizer Inc. (PFE) were trading up +0.75 or +2.29 percent to $33.55 per share in Tuesday’s premarket after the company reported better than expected earnings and revenue for its fiscal first quarter earlier this morning. Pfizer stock closed at $32.90, up +0.09 or +0.28 percent in Monday’s regular trading session.

Stock Analysis

Incorporated in 1942, New York City based Pfizer Inc. is a global research based biopharmaceutical company and the largest company of its kind in the world by revenue.
Pfizer’s products include a wide variety of medicines, vaccines, medical devices and healthcare products. The company’s best known pharmaceutical brands include Lipitor, used for lowering cholesterol, Diflucan, an oral antifungal medication, Viagra, for erectile dysfunction and Celebrex, an anti-inflammatory drug. The company’s pipeline is an industry leader and is currently working on developing treatments for cancer and Alzheimer’s disease.

For Pfizer’s first quarter, the company reported net income of $3.02 billion or $0.49 per share compared to $2.38 billion or $0.38 per share in the same period one year ago. After the exclusion of some items, Pfizer earned $0.67 per share in the quarter, while revenue came to $13.01 billion an increase of +19.7 percent over the previous year’s first quarter. The analyst consensus was for earnings of $0.55 per share on $12.0 billion in revenue.

This quarter is the first in which Pfizer includes the results of its September, 2015 acquisition of Hospira Inc. It is also the first quarter reported since the termination of the $160 billion merger agreement with Allergan Plc (AGN) as U.S. regulators cracked down on so-called “tax inversion” deals earlier this month.

Ian Read, Pfizer’s Chairman and Chief Executive Officer stated in the earnings release that, “I believe this performance results from our Company being well positioned in terms of product portfolio, organizational structure and leadership, as well as by our continued strong financial flexibility. In addition, our late stage product pipeline is increasingly ready to deliver our next set of prospective growth drivers with competitive positions in high-potential therapeutic areas where I believe Pfizer can be a leader.” Read continued saying, “In addition, we have made excellent progress integrating the legacy Hospira operations and now expect to achieve $1.0 billion of Hospira cost savings by 2018, 25% more than our initial cost savings target of $800 million.”

The company’s innovative products division reported sales of $7.03 billion in the quarter, while the established products segment reported $5.97 billion. Prevnar vaccine products sales increased to $1.51 billion, while the company’s cancer drug, Ibrance had sales of $429 million. Analysts expected sales of $1.4 billion for Prevnar and $393 million for Ibrance.

Pfizer upwardly revised its guidance for 2016’s full year. The company now expects revenue to be between $51 billion and $53 billion, up from $49 billion to $51 billion with adjusted earnings of $2.38 to $2.48 per share compared to a previous $2.20 to $2.30 per share.

Other News About PFE

Ohio Medicaid gets $25M from Pfizer drug discount settlement

State attorney general alleged the company didn’t give Medicaid the same discounts as private buyers of the heartburn drug Protonix.

Pfizer Hosts Annual Meeting of Shareholders

The company also declared a $0.30 dividend for the second quarter, its 310 consecutive quarterly dividend.

Other Stocks in the News

Fiat, Google Plan Partnership on Self-Driving Minivans

Companies will enter the first phase of a joint project for the development of a self-driving vehicle.

Halliburton adjusted profit beats estimate, helped by cost cuts

Company beat estimates for earnings by $0.03 per share.

Published on May 3, 2016
By Jay Hawk
Jay Hawk
Jay Hawk enjoyed a 12-year professional financial markets career incorporating extensive first hand futures and options experience obtained by trading in the stock, commodity and forex markets on U.S. exchanges. Since retiring as a full-time financial market professional, he has been actively trading stock, commodities, forex and options for his own account and managing funds for others, as well as writing financial market commentary and educational articles.

Copyrighted 2016. Content published with author's permission.

Posted in ...